Rheonix
Rheonix is a US-based biotechnology company founded in 2007 that develops automated molecular testing platforms integrating purification, amplification, and detection, serving clinical and applied diagnostics laboratories.
- Company typePrivate
- Founded2007
- HeadquartersIthaca, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rheonix does
Rheonix is a privately held US biotechnology company headquartered in Ithaca, New York, founded in 2007, with a headcount of 51-100 employees. The firm develops automated molecular testing solutions built around an interchangeable platform architecture that consolidates sample purification, nucleic acid amplification, and detection into a single integrated workflow, removing the fragmentation that characterizes traditional multi-step molecular diagnostics. The offering targets clinical and applied testing laboratories that require standardized, repeatable molecular assays with reduced hands-on time and minimized manual transfer steps.
The business model is B2B, monetizing through sales (or licensing) of automated instruments and recurring consumables (cartridges, reagents) to diagnostic laboratories, research institutions, and potentially applied testing verticals. The platform's modularity supports menu expansion across assay types and serves as a natural anchor for pull-through consumables revenue. Direct customer, channel, and pricing information is not disclosed in the input.
Rheonix has sustained operations through at least eleven private capital raises across 2010 to 2019, totaling approximately $86.7M. The investor syndicate is concentrated in Upstate New York–focused VCs (Cayuga Venture Fund, Rand Capital, Onondaga Venture Capital Fund, Limestone Capital Advisors) alongside out-of-region backers such as Gefinor Capital and Advantage Capital. The company has not pursued an IPO and remains private. Gregory J. Galvin serves as CEO & Chairman and Tony Eisenhut as President; no other management, contact, regulatory, M&A, or product launch events are present in the available input.
Rheonix firmographics
Firmographics- Name
- Rheonix
- Legal name
- frightcatalog.com
- Website
- https://rheonix.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Rheonix is a US-based biotechnology company founded in 2007 that develops automated molecular testing platforms integrating purification, amplification, and detection, serving clinical and applied diagnostics laboratories.
- Ownership category
- akta.pro rank
Rheonix industry classification
Industry- Product category
- Molecular Diagnostics / Lab Automation Instruments
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)
- akta.pro secondary industry
- Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)
Keywords
Where Rheonix is headquartered
LocationHeadquarters
- HQ city
- Ithaca
- HQ country
- United States
- HQ region
- North America
Markets served
Rheonix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Supply Chain, Infrastructure, Marketing or Sales
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Standard lottery betting rates |
Distribution channels1 record
Marketing channels1 record
Rheonix product offering
Product offeringCore offering
Rheonix develops automated molecular testing solutions built around interchangeable functional modules for purification, amplification, and detection of nucleic acids. The company sells benchtop or platform-scale instruments paired with single-use microfluidic cartridges and reagent kits that allow laboratories to run end-to-end sample-to-answer molecular workflows with minimal manual handling. Its products target clinical diagnostic labs and life-science research users that need flexible, consolidated molecular testing on a single instrument family.
Differentiator
Problem solved
Functional benefit
Products and services
- Automated Molecular Testing Platform (Rheonix system family) Fully automated molecular testing instrument family that consolidates nucleic-acid sample preparation, amplification, and detection on a single benchtop or platform. It is designed for clinical diagnostic and research laboratories that need a flexible, closed workflow across multiple test menus.
- Interchangeable Microfluidic Cartridges and Reagent Kits Single-use disposable cartridges and matched reagent kits that perform interchangeable purification, amplification, or detection functions on the Rheonix platform. They enable laboratories to switch test types and applications on the same instrument family and provide recurring consumable pull-through revenue.
Companies that use Rheonix
Customer profileSegments1 record
Ideal customer profiles2 records
Rheonix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Rheonix partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights3 records
Rheonix competitors and assessment
Company assessmentDirect peers
- Cepheid: Cepheid (now part of Danaher) is the market-leading developer of sample-to-answer molecular diagnostic systems (GeneXpert). It directly competes with Rheonix in the automated, cartridge-based molecular testing space for clinical and hospital labs.
- GenMark Diagnostics: GenMark's ePlex system delivers fully automated sample-to-answer molecular detection across syndromic panels, making it a head-to-head platform competitor to Rheonix's automated molecular testing solution.
- BioFire Diagnostics: BioFire (part of bioMérieux) markets the FilmArray multiplex automated molecular diagnostic system, the closest functional analog to Rheonix's interchangeable purification/amplification/detection workflow.
- NeuMoDx Molecular: NeuMoDx (now part of QIAGEN) developed an automated, high-throughput sample-to-answer molecular diagnostic platform with random-access workflow — closely matching Rheonix's stated value proposition of interchangeable test steps.
Broad incumbents
- QIAGEN: QIAGEN serves the molecular diagnostics and life-science tools market broadly, including sample-prep-to-result workflows (now incorporating NeuMoDx). It is an incumbent competitor and prospective ecosystem partner for Rheonix.
- Abbott Molecular: Abbott's m2000 system is an established automated molecular diagnostic platform in clinical labs; comparable to Rheonix in workflow automation and target menu, but fielded by a global diagnostics conglomerate.
- Hologic: Hologic markets the Panther Fusion system for automated molecular diagnostics across women's health and infectious disease menus. As a broad diagnostics incumbent, it overlaps with Rheonix in clinical molecular testing but operates at much greater scale.
- Becton Dickinson (BD MAX): BD's MAX System is an automated molecular diagnostic platform with a syndromic menu for enteric, respiratory, and STI testing — a directly relevant comparator to Rheonix's automated sample-to-answer architecture.
- Roche Diagnostics: Roche operates the cobas Liat and cobas 6800/8800 molecular diagnostic systems, serving a broad range of lab customers with automated sample-to-answer and high-throughput molecular testing — overlapping with Rheonix's clinical molecular test menus.
Emerging players
- Meridian Bioscience: Meridian develops and commercializes molecular diagnostic tests and immunoassay kits used in clinical labs. As a smaller, assay-focused diagnostics company, it is comparable to Rheonix in scale and menu-driven business model, though without an integrated automated platform.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Rheonix social profiles
Digital presenceRheonix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rheonix leadership team
Management profileNumber of profiles
Profiles2 records
Rheonix funding detail
Funding detailFunding overview
Funding rounds11 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rheonix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rheonix
What does Rheonix do?
Rheonix develops automated molecular testing solutions built around interchangeable functional modules for purification, amplification, and detection of nucleic acids. The company sells benchtop or platform-scale instruments paired with single-use microfluidic cartridges and reagent kits that allow laboratories to run end-to-end sample-to-answer molecular workflows with minimal manual handling. Its products target clinical diagnostic labs and life-science research users that need flexible, consolidated molecular testing on a single instrument family.
Is Rheonix a public or private company?
Rheonix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Rheonix founded?
Rheonix was founded in 2007. It employs 51 to 100 people.
Where is Rheonix based?
Rheonix is headquartered in Ithaca, United States, in the North America region.
Who are Rheonix's main competitors?
Direct peers on record are Cepheid, GenMark Diagnostics, BioFire Diagnostics and NeuMoDx Molecular. Broad incumbents are QIAGEN, Abbott Molecular, Hologic, Becton Dickinson (BD MAX) and Roche Diagnostics. Meridian Bioscience is listed as an emerging player.
Does Rheonix have an API?
No public API is recorded for Rheonix.
What industry is Rheonix in?
Rheonix's product category is Molecular Diagnostics / Lab Automation Instruments. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays, with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 621511 and its SIC code is 2835.